Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Immune modulators help anti-TNF agents battle Crohn’s disease, but not UC

Publish date:: June 27, 2019

Key clinical point: Adding an immune modulator to anti-TNF initiation therapy benefits patients with Crohn’s disease but not those with ulcerative colitis.

Major finding: For patients with CD, combination therapy with an immune modulator and an anti-TNF agent decreased risk of ineffectiveness by 38%, compared with anti-TNF therapy alone.

Study details: A retrospective study involving 852 patients with Crohn’s disease and 303 patients with ulcerative colitis.

Disclosures: The study was funded by Crohn’s and Colitis Canada Grants in Aid of Research and the Helmsley Foundation. The investigators reported financial relationships with AbbVie Canada, Takeda Canada, Merck Canada, and others.

Citation:

Targownik LE et al. Clin Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1016/j.cgh.2018.11.003.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,